The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations (Q38089699)

From Wikidata

Jump to navigation Jump to search

scientific article published on April 2013

Language	Label	Description	Also known as
English	The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations	scientific article published on April 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

0 references

systematic review

1 reference

based on heuristic

inferred from title

object named as

Paul McCrone

2

0 references

author name string

Evanthia Achilla

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

publication date

1 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Applied Health Economics and Health Policy

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

95-106

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

A systematic review of the prevalence of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

The global costs of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Relapse in schizophrenia: costs, clinical outcomes and quality of life

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Second-generation antipsychotic long-acting injections: systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Cost effectiveness of long-acting risperidone in Sweden

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

How do clinical trial participants compare to other patients with schizophrenia?

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Long-term observation of patients successfully switched to risperidone long-acting injectable: A retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use.

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Costs of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0016-2

21 January 2018

Identifiers

10.1007/S40258-013-0016-2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38089699&oldid=2201257203"